Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 244 participants.

Also called NCT01414166

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 244 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01414166
  • CTRI CTRI/2012/08/002873
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01414166. Randomized; quadruple masking; primary purpose treatment. Start 2011-09 (registry gives no type); primary completion 2013-02 (actual). Results posted on 2014-03-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)
Condition
Dyslipidemia
Intervention (Drug)
ERN/LRPT
Intervention (Drug)
placebo
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01414166
Content hash
e3b85927bc5cf48e916dc7c07f51e13067c908e37d3e7f0df353da521f42b97e